Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice

Research output: Contribution to journalArticleResearchpeer-review

77 Citations (Scopus)


In 596 patients with RA managed over a decade in a community practice setting, 879 slow acting antirheumatic drug (SAARD) treatment episodes were analyzed using 5-year life tables. The probability of termination of therapy reached 50% by 9-24 months for all drugs except for methotrexate (MTX), which had reached only 62% by 5 years. MTX treatments were of significantly longer duration than those of all other SAARD (p < 0.001); terminations for both inefficacy (p < 0.001) and toxicity (NS) were less likely. These findings concur with recent evidence suggesting that MTX is a superior SAARD in this setting.

Original languageEnglish
Pages (from-to)704-708
Number of pages5
JournalThe Journal of Rheumatology
Issue number5
Publication statusPublished - 1 Jan 1992
Externally publishedYes


  • antirheumatic drugs
  • community practice
  • methotrexate
  • rheumatoid arthritis
  • statistics

Cite this